Enhance Viability of Antigen-Presenting Cells for Cell-Based Therapy

Our technology aims to enhance the efficacy of cancer cell therapy using antigen-presenting cells like dendritic cells (DCs) and macrophages. These cells typically have short lifespans due to apoptosis, limiting their therapeutic potential. By expressing a Bcl-2 family apoptosis inhibitor, our technology significantly extends the survival of these cells. This innovation has demonstrated promising results in both in vitro and in vivo studies, showing enhanced survival and potential for stronger therapeutic effects in cancer treatment.